AnalystsInsight

Ann Hynes (Mizuho Securities): Analyst Track Record and Price‑Target Accuracy

How often Ann Hynes’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 2,291 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Ann Hynes ranks #703 of 1,121 analysts in Exent’s scoring (4.7★).
  • 61.4% of price targets were reached over 7 years, versus 53.6% for the average analyst.
  • Median time to reach a target: 90 days; 62.0% of calls were up 12 months later.
  • Most‑covered stocks: ELV, HUM, CNC, UNH.
  • Free on Exent: Ann Hynes’s full record, with ratings 3 days after publication.

Ann Hynes’s track record at a glance

Ann Hynes of Mizuho Securities ranks #703 of the 1,121 analysts Exent scores, with a 4.7★ rating and a focus on healthcare. Over a 7‑year lookback, 61.4% of Ann’s price targets were reached, 7.8 points above the 53.6% average across all analysts.

MetricAnn HynesAll analysts
Price‑target hit rate61.4%53.6%
Median days to hit target90 days91 days
Calls up after 12 months62.0%64.6%
Median 12‑month return of calls+10.1%+13.4%
Hit rate, last 2 years65.1%—
Average worst drop after a call−18.6%—
Ratings in the sample2,291—
Stocks covered31—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetAnn Hynes
Under 30 days22.2%
30–90 days28.0%
90–180 days27.4%
Over 180 days22.4%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Ann Hynes covers most

StockRatings in the sample
ELV31
HUM28
CNC27
UNH25
FTRE23
BTSG23
CVS23
MOH22

In the past year Ann’s ratings were 73% Buy, 27% Hold and 0% Sell.

Ann Hynes’s latest ratings

DateStockActionRatingPrice target
Oct 13, 2026HUMMaintained: BuyBuy$495.00
Oct 7, 2026IQVMaintained: BuyBuy$300.00
Oct 7, 2026IQVReiterated: BuyBuy$300.00
Oct 7, 2026MEDPMaintained: BuyBuy$700.00
Oct 7, 2026MEDPReiterated: BuyBuy$700.00
Sep 25, 2026CRLReiterated: HoldHold$295.00
Aug 11, 2026MDReiterated: HoldHold$28.00
Aug 11, 2026EHCReiterated: BuyBuy$140.00
Aug 10, 2026CONReiterated: BuyBuy$40.00
Aug 10, 2026CRLReiterated: HoldHold$264.00
Aug 10, 2026LHReiterated: BuyBuy$355.00
Aug 10, 2026THCReiterated: BuyBuy$290.00
  • Oct 13, 2026
    Stock
    HUM
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $495.00
  • Oct 7, 2026
    Stock
    IQV
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $300.00
  • Oct 7, 2026
    Stock
    IQV
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $300.00
  • Oct 7, 2026
    Stock
    MEDP
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $700.00
  • Oct 7, 2026
    Stock
    MEDP
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $700.00
  • Sep 25, 2026
    Stock
    CRL
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $295.00
  • Aug 11, 2026
    Stock
    MD
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $28.00
  • Aug 11, 2026
    Stock
    EHC
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $140.00
  • Aug 10, 2026
    Stock
    CON
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $40.00
  • Aug 10, 2026
    Stock
    CRL
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $264.00
  • Aug 10, 2026
    Stock
    LH
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $355.00
  • Aug 10, 2026
    Stock
    THC
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $290.00

Ann’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Oct 20, 2026; ranking updated Oct 21, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Ann Hynes’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Ann Hynes ranks #703 of 1,121 with a 4.7★ rating. 61.4% of price targets were reached over a 7-year lookback (all analysts: 53.6%), and 62.0% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Ann Hynes’s success rate is 60.1% by the ranking source and 61.4% by Exent’s price-target hit-rate backtest, with a median of 90 days to reach a target.

Ann Hynes (Mizuho Securities) covers 31 stocks, mostly in healthcare. The most frequently rated are ELV, HUM, CNC, UNH, FTRE.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.